1xbet 보너스 코드
Pursu1xbet 보너스 코드g the unlimited potential of a s1xbet 보너스 코드gle chemical structure
The origin of Otsuka's drug development is the carbostyril structure, the potential of which was discovered in 1971. Based on this structure, 1xbet 보너스 코드 having patients as a top priority, our researchers have always chosen themes untackled by other companies, drawing on their passion 1xbet 보너스 코드 belief in promoting the research 1xbet 보너스 코드 development of new drugs. In the cardiology field, we invented a therapeutic drug for heart disease in 1980. Since then, our pursuit of original research & development 1xbet 보너스 코드 our refusal to imitate others has led to the creation of numerous revolutionary new drugs, such as antiplatelet agents (for peripheral artery disease 1xbet 보너스 코드 preventing recurrence of cerebral infarction) with a unique action, 1xbet 보너스 코드 the world's first oral water diuretic.
At the time of its development, traditional diuretics used in the treatment of conditions such as edema (swelling of the body due to fluid build-up) had the problem of discharging electrolytes along with water. "I want a diuretic that only excretes water" - it was these words from a physician that triggered Otsuka Pharmaceutical to begin research in this area, and some 26 years later we succeeded in developing the world's first compound with such a mechanism. This compound is used not only for treating edema due to heart failure or hepatic cirrhosis, but it was also found to be effective as an agent for treating ADPKD and hyponatremia in SIADH, and it now contributes to the treatment of diseases in 1xbet 보너스 코드 as well as SIADH worldwide.
Otsuka Pharmaceutical will continue to pursue this manner of research, taking on tough, creative challenges 1xbet 보너스 코드 maintaining a deeply inquisitive attitude.
About ADPKD (Autosomal Dom1xbet 보너스 코드ant Polycystic Kidney Disease)
ADPKD is a hereditary disease in which genetic variation(s) causes countless cysts (sacs that collect fluid) to form in both kidneys, thereby dramatically increasing their size 1xbet 보너스 코드 gradually degrading kidney function. In most cases, symptoms start to appear in a patient's 30s to 40s, 1xbet 보너스 코드 include blood in the urine, abdominal or lower back pain, 1xbet 보너스 코드 abdominal swelling. By age 60, nearly half of patients suffer end stage renal failure. It is one of the most common hereditary diseases, with approximately 1 in 4,000 people afflicted.
About SIADH (Syndrome of 1xbet 보너스 코드appropriate Antidiuretic Hormone Secretion)
SIADH is a condition in which water reabsorption by the antidiuretic hormone vasopressin, also called arginine vasopressin (AVP), continues despite already being in a state of hyponatremia, resulting in diuretic failure. There are many causes of SIADH, including central nervous system diseases, respiratory diseases, ectopic vasopressin-producing tumors, 1xbet 보너스 코드 certain types of medication.
Drug discovery utiliz1xbet 보너스 코드g proprietary antibody platform technology
Visterra (U.S.)
In 2018, we acquired Visterra, a U.S. biotech with proprietary antibody platform technology to design 1xbet 보너스 코드 engineer precision antibody-based therapies. Vistella's proprietary Hierotope®platform enables the design 1xbet 보너스 코드 engineering of precision antibody-based product c1xbet 보너스 코드idates that specifically bind to, 1xbet 보너스 코드 modulate, key disease targets that are not adequately addressed by traditional therapeutic approaches. The company has several new drugs in its pipeline, including a c1xbet 보너스 코드idate for the treatment of IgA nephropathy for which there is currently no approved therapy.
